产次、绝经激素治疗与卵巢颗粒细胞瘤风险:基于人群的病例对照研究
该研究基于芬兰癌症登记处1994-2015年确诊的505例成人型卵巢颗粒细胞瘤(AGCT)女性及每例5名年龄匹配对照,评估产次和绝经后激素治疗(HT)与AGCT风险的关系。结果显示产次及首次或末次分娩年龄对AGCT风险无显著影响;使用单纯雌二醇治疗至少5年及连续雌二醇-孕激素治疗6个月至5年者后续AGCT风险显著降低(OR分别为0.28和0.23)。结论认为AGCT发展与产次无明显关联,绝经后HT使用者未见AGCT风险增加。
要点
- 产次及首次或末次分娩年龄对AGCT风险无显著影响。
- 单纯雌二醇治疗≥5年者AGCT风险显著降低(OR 0.28)。
- 连续雌二醇-孕激素治疗6个月至5年者AGCT风险显著降低(OR 0.23)。
核心结论
- 与上皮性卵巢癌不同,AGCT发展未显示与产次明确相关,绝经后HT使用者未见AGCT风险增加。
研究设计与样本
- 基于芬兰癌症登记处的病例对照研究,纳入1994-2015年确诊的505例AGCT女性,每例匹配5名年龄对照。
主要发现
- 产次及首次或末次分娩年龄对AGCT风险无显著影响。
- 20.4%的后续确诊AGCT女性曾使用全身性绝经后HT。
- 使用单纯雌二醇治疗至少5年者后续AGCT风险显著降低(OR 0.28;95%CI 0.08-0.94)。
- 使用连续雌二醇-孕激素治疗6个月至5年者后续AGCT风险显著降低(OR 0.23;95%CI 0.08-0.71)。
关键数值与推荐
- 单纯雌二醇治疗至少5年与后续AGCT风险降低相关(OR 0.28;95%CI 0.08-0.94)。
- 连续雌二醇-孕激素治疗6个月至5年与后续AGCT风险降低相关(OR 0.23;95%CI 0.08-0.71)。
临床怎么用
- 对于AGCT风险担忧的绝经后女性,使用单纯雌二醇或连续雌二醇-孕激素方案未见AGCT风险增加。
- 产次不应作为AGCT风险评估的独立参考因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Adult-type ovarian granulosa cell tumors (AGCTs) are hormonally active neoplasms with limited epidemiological data available. We evaluated the effect of parity and postmenopausal hormone therapy (HT) use on the risk of AGCT in a population-based case-control setting. METHODS: We identified all women diagnosed with AGCT during 1994-2015 (n = 505) from the Finnish Cancer Registry. For each case, five controls matched for age were selected from the National Population Registry, which also provided data on parity and ages at deliveries. Information on postmenopausal HT by different regimens (estradiol-only, sequential estrogen-progestin and continuous estrogen-progestin) was obtained from nationwide Prescription Register. The association between parity, ages at deliveries, HT use, and AGCT incidence was evaluated by odds ratios (ORs) using a conditional logistic regression model and stratified by age at index date (<55 years or ≥ 55 years). RESULTS: Parity and age at first or last delivery had no significant effect on AGCT risk. Systemic postmenopausal HT had been used by 20.4% of women who were later diagnosed with AGCT. The risk for subsequent AGCT was significantly decreased among users of estradiol-only therapy for at least five years (OR 0.28; 95% confidence interval 0.08-0.94) and continuous estradiol-progestin therapy for 6 months to 5 years (0.23; 0.08-0.71). CONCLUSIONS: Unlike in epithelial ovarian cancer, AGCT development is not clearly associated with parity, and users of postmenopausal HT do not seem to carry an excess risk for AGCT formation.
引用
- Bryk S, Katuwal S, Haltia UM, et al. Parity, menopausal hormone therapy, and risk of ovarian granulosa cell tumor - A population-based case-control study. Gynecol Oncol. 2021. PMID: 34598830. doi:10.1016/j.ygyno.2021.09.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。